N-(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden)-N'-(1-pyridin-2-yl-methylidene)azine | 1255954-01-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N-(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden)-N'-(1-pyridin-2-yl-methylidene)azine
• CAS: 1255954-01-8
• 化学式: C₂₂H₁₆BrN₅
• 分子量: 430.307
• InChiKey: MSARMCJFLIPVHW-UHFFFAOYSA-N

反应信息

• 作为反应物：
  描述：

  copper(II) choride dihydrate 、 N-(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden)-N'-(1-pyridin-2-yl-methylidene)azine 以 甲醇 为溶剂， 生成 (C16H10(Br)N2NHNCHC5H4N)Cu(chloride)2
  参考文献：
  名称：

  具有修饰的吲哚[3,2- c ]喹啉配体的高细胞毒性铜（II）配合物的结构-活性关系。

  摘要：

  在内酰胺单元上合成并修饰了许多吲哚并[3，2- c ]喹啉，以提供能够容纳金属离子的外围结合位点。潜在的三齿配体HL 1a - HL 4a和HL 1b - HL 4b与氯化铜（II）在异丙醇/甲醇中反应，得到新颖的五配位铜（II）配合物[Cu（HL 1a - 4a）Cl 2 ]和[ Cu（HL 1b - 4b）Cl 2 ]。此外，一种新的络合物[Cu（HL 5b）Cl 2]和两个以前报道的化合物[Cu（HL 6a）Cl 2 ]和[Cu（HL 6b）Cl 2 ]与修饰的paullone配体HL 5b，HL 6a和HL 6b，可以认为是吲哚喹啉HL 1b的相似物为了比较，合成了其中吡啶环被七元氮杂环庚环正式取代的HL，HL 4a和HL 4b。新的配体和铜（II）配合物的特征是1 H和13C NMR，IR和电子吸收光谱，ESI质谱，在298 K（[Cu（HL 1a）Cl 2 ]和[Cu（HL 4b）Cl

  DOI：

  10.1021/ic101633z
• 作为产物：
  描述：

  吡啶-2-甲醛 、 (9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6-yl)hydrazine 以 甲醇 为溶剂， 反应 0.75h， 以68%的产率得到N-(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden)-N'-(1-pyridin-2-yl-methylidene)azine
  参考文献：
  名称：

  Highly Cytotoxic Copper(II) Complexes with Modified Paullone Ligands

  摘要：

  The reaction of copper(II) chloride or copper(II) acetate with 6-N-(2-N',N'-dimethylaminoethylamino)-7,12-dihydroindolo-[3,2-d][1]benzazepine (HL1), 9-bromo-6-N-(2-N',N'-dimethylaminoethylamino)-7,12-dihydroindolo[3,2-d][1]-benzazepine (HL2), N-(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden-N'-(1-pyridin-2-yl-methylidene)azine (HL3), or N-(9-bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-yliden-N'-(1-pyridin-2-yl-ethylidene)azine (HL4) in methanol affords the novel copper(I-I) complexes [Cu(HL1)Cl-2] (1). [Cu(HL2)Cl-2] (2). [Cu(HL3)Cl-2] (3), [Cu(HL4)Cl-2] (4), and [Cu(L-4)(CH3COO)(CH3OH)] (5). The new ligands (HL2 and HL3) and the complexes 1-5 were characterized by H-1 and C-13 NMR, IR and electronic absorption spectroscopy, ESI mass spectrometry, and X-ray crystallography. Two ligands, HL1 and HL2, and complexes 1-4 were tested for cytotoxicity in three human cancer cell lines, namely, CH1 (ovarian carcinoma), A549 (non-small cell lung cancer), and SW480 (colon carcinoma). Additionally, complexes 1, 2, and 4 were assayed in an isogenic pair of ovarian cancer cell lines, one being sensitive to cisplatin (A2780) and the other having acquired cisplatin resistance (A2780cisR). All of the compounds evaluated are cytotoxic, with complexes 3 and 4 exhibiting IC50 values in the nanomolar range.

  DOI：

  10.1021/ic902042a